New MRD Assessment Data Using clonoSEQ® To Be Presented at 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Read More

Adaptive Goes Public

In one of the biggest biotech IPOs of the year, Harlan and Chad Robins ring the Nasdaq opening bell as Adaptive is listed under the ticker symbol ADPT.

clonoSEQ Covered by Medicare

Patients with certain blood cancers are ensured access by Medicare for MRD assessment to support more personalized treatment decisions. This paves the way for further coverage by private payers.